Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis

References

• Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31(19):2369-429
   PubMed Web of Science ®Google Scholar
• The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347(23):1825-33
   PubMedGoogle Scholar
• Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med 2012;172(13):997-1004
   PubMedGoogle Scholar
• Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004;109(16):1973-80
   PubMed Web of Science ®Google Scholar
• Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Europace 2014;16:162-73
   PubMedGoogle Scholar
• Eldstrom J, Wang Z, Xu H, et al. The molecular basis. of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1. 5 channels. Mol Pharmacol 2007;72(6):1522-34
   PubMed Web of Science ®Google Scholar
• Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007;16(4):519-32
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant – a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs 2008;17(5):805-10
   PubMed Web of Science ®Google Scholar
• Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16(11):1227-38
   PubMed Web of Science ®Google Scholar
• Tian D, Frishman WH. A. new drug to treat patients with acute onset atrial fibrillation. Cardiol Rev 2011;19(1):41-4
   PubMed Web of Science ®Google Scholar
• Mao ZL, Wheeler JJ, Clohs L, et al. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol 2009;49(1):17-29
   PubMed Web of Science ®Google Scholar
• Cheng JWM, Rybak I. Pharmacotherapy options in atrial fibrillation: focus on vernakalant. Clin Med Therapeutics 2009;1:215-30
   Google Scholar
• Roy D, Rowe BH, Stiell IG, et al. CRAFT Investigators. A randomized controlled trial of RSD 1235, a novel antiarrhythmic agent in treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44(12):2355-61
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt CM, Torp-Pedersen C, et al. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117(12):1518-25
   PubMed Web of Science ®Google Scholar
• Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant Hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circulation 2009;2(6):652-9
   PubMedGoogle Scholar
• Pratt CM, Roy D, Torp-Pederson C, et al. Usefulness of Vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010;106(9):1277-83
   PubMed Web of Science ®Google Scholar
• Torp-Penderson C, Camm AJ, Butterfield NN, et al. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease. Int J Cardiol 2013;166(1):147-51
   PubMedGoogle Scholar
• Camm AJ, Capucci A, Hohnloser SH, et al. AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57(3):313-21
   PubMed Web of Science ®Google Scholar
• Conde D, Costabel JP, Caro M, et al. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol 2013;168(3):2423-5
   PubMed Web of Science ®Google Scholar
• Conde D, Costabel JP, Martin A, et al. Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation. Cardiovasc Ther 2013;31(6):377-80
   PubMedGoogle Scholar
• Stiell IG, Roos JS, Kavanagh KM, et al. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J 2010;159(6):1095-101
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097
   PubMed Web of Science ®Google Scholar
• Camm AJ, Toft E, Torp-Pedersen C, et al. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. Europace 2012;14(6):804-9
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Raev DH, Dickinson G, et al. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol 2011;4(5):637-43
   PubMed Web of Science ®Google Scholar
• Cardiome provides update on Merck’s development plans for vernakalant oral. Available from: www.cardiome.com/investors/news/archives/2012/cardiome-provides-update-mercks-development-plans-vernakalant-oral [Last accessed 23 April 2014]
   Google Scholar
• Merck returns to Cardiome all rights to atrial fibrillation drug vernakalant. Available from: www.forbes.com/sites/larryhusten/2012/09/26/merck-returns-to-cardiome-all-rights-to-atrial-fibrillation-drug-vernakalant/ [Last accessed 23 April 2014]
   Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33(21):2719-47
   PubMed Web of Science ®Google Scholar
• www.cardiome.com/pipeline/atrial-fibrillation/vernakalant-iv [Last accessed 23 April 2014]
   Google Scholar